Cookie Policy

We've put some small files called essential cookies on your device to help our site work on your browser.
We also use analytical cookies to help up improve our website by collecting and reporting information on it's usage.

You can read more above this on our Privacy Policy page.

I'm ok with analytical cookies Do not use analytics cookies

2021 Annual Report and 2022 AGM Notice

30 Jun 2022

Shield Therapeutics plc announces that the following documents have now been sent to shareholders:

  • Annual Report and Accounts for the year ended 31 December 2021
  • Notice of Annual General Meeting (“AGM”) 2022

In accordance with AIM Rule 26, these documents are also available to view on the Company’s website: https://www.shieldtherapeutics.com/corporate-documents/

We are delighted to be able to welcome back our shareholders who are able to join us at our AGM. This year the Company’s AGM will be held at 2pm (BST) on 27 July 2022 at the offices of Shield Therapeutics plc, Northern Design Centre, Baltic Business Quarter, Gateshead Quays, England NE8 3DF. Should restrictions be imposed that prevent this Meeting from being held in person the Company has made provisions for this Meeting to be held both virtually and electronically and details will be provided to shareholders.

If you wish to attend the AGM in your capacity as a shareholder, please bring proof of shareholding or if shares are held through a nominee account, a letter of representation, to facilitate your entry to the Meeting.

The Company will provide a facility for shareholders to join the AGM online and telephonically and there will be an opportunity for shareholders to ask questions. In order to facilitate the process, the Board would request that shareholders register for the meeting and submit questions in advance, before 2.00pm (BST) on 25 July 2022.To register for dial-in details and to submit any questions please contact Walbrook PR via email at shield@walbrookpr.com or call +44 (0)20 7933 8787. For more details click here.

Back to news